Fitchen J H, Cline M J
Br J Haematol. 1980 Jan;44(1):7-16. doi: 10.1111/j.1365-2141.1980.tb01178.x.
A modification of the microcytotoxicity assay of Terasaki & McClelland was used to screen for serum inhibitors of myeloid progenitor cells (CFU-C). Sera from 104 patients with neutropenia or bone marrow failure and from 104 controls, including 30 normal subjects and 74 patients with various disorders or multiple transfusions, were studied. Inhibitors of CFU-C were found in 19 of the 104 patients with neutropenia or marrow failure: three with acquited neutropenia and 16 with aplastic anaemia. In 17 of the 19 patients the inhibitor was either complement dependent or chavincingly associated with clinical remission of disease in one patient. In another patient, the inhibitor was an IgG antibody directed against non-HL1 antigens present on CFU-C of all 50 normal target marrows tested; however, it was not clearly autoreactive. Inhibitors were also found in one of nine patients with lupus erythematosus, one with breast carcinoma, one patient with renal transplant rejection, and six of 46 multiply transfused patients without marrow failure. Our findings indicate that most serum inhibitors are associated with multiple transfusion: convincing evidence of pathogenetically important autoreactive antibody was present in only one of 19 patients with inhibitors.
采用对寺崎和麦克莱兰微量细胞毒性试验的一种改良方法，来筛选骨髓祖细胞（CFU-C）的血清抑制剂。研究了104例中性粒细胞减少症或骨髓衰竭患者以及104名对照者的血清，对照者包括30名正常受试者以及74例患有各种疾病或多次输血的患者。在104例中性粒细胞减少症或骨髓衰竭患者中，有19例发现了CFU-C抑制剂：3例为获得性中性粒细胞减少症，16例为再生障碍性贫血。在这19例患者中的17例，抑制剂要么依赖补体，要么与1例患者的疾病临床缓解密切相关。在另1例患者中，抑制剂是一种IgG抗体，针对所有50份检测的正常靶骨髓CFU-C上存在的非HL1抗原；然而，它并非明显的自身反应性。在9例红斑狼疮患者中的1例、1例乳腺癌患者、1例肾移植排斥患者以及46例无骨髓衰竭的多次输血患者中的6例也发现了抑制剂。我们的研究结果表明，大多数血清抑制剂与多次输血有关：在19例有抑制剂的患者中，仅有1例存在具有致病重要性的自身反应性抗体的确凿证据。
